Ernexa Therapeutics Inc. Nasdaq Delisting Warning: What You Need to Know

1. What happened?

Ernexa Therapeutics Inc. just received a warning from Nasdaq. The stock exchange sent this notice on March 18, 2026. Their stock price has been too low. It traded below the required $1.00 per share for 30 business days. They did a "reverse stock split" recently. This combines multiple shares into one to boost the price. Because of this, Ernexa won't get the usual grace period. Most companies receive this period in similar situations. Ernexa must now fight to keep its shares listed on Nasdaq. Otherwise, it faces delisting.

2. When did it happen?

The news officially came out on March 18, 2026. Such announcements often come after market close or before opening. This lets the market process information. It prevents immediate, volatile trading.

3. Why did it happen? (context and background)

Let's understand why this happened. We'll look at the backstory. Nasdaq has a rule, Listing Rule 5550(a)(2). It requires listed companies to keep a $1.00 minimum share price. Ernexa's stock traded below $1.00 for 30 business days. This triggered the non-compliance notice. Normally, companies get a 180-day "compliance period." This grace period lets them fix the issue. They must get their stock price above $1.00 for at least 10 business days.

Ernexa cannot get this standard grace period. They performed a reverse stock split within the last year. Nasdaq sees a reverse stock split as artificial. It boosts the price, but doesn't show better business performance. So, Nasdaq does not give the usual compliance period to companies using this method. This event directly results from their low stock price. It also comes from Nasdaq's specific listing rules.

4. Why does this matter? (impact and significance)

This is a big deal. If Ernexa fails to meet Nasdaq's minimum price, its shares could be "delisted." This means removal from the Nasdaq exchange.

• If delisting happens: Delisting makes buying and selling shares much harder. The stock would move to a less regulated "over-the-counter" (OTC) market. Examples include the OTC Bulletin Board (OTCBB) or Pink Sheets. This move usually cuts the stock's liquidity greatly. It also creates wider bid-ask spreads. This often lowers the stock's value significantly. Investors lose confidence, and institutions participate less.

Delisting also harms the company's reputation. It becomes harder to attract new investors. Raising capital or getting good loans becomes tough. This affects future equity offerings or debt financing. This hinders funding for research and development. It also limits expanding operations or pursuing strategic plans. Ultimately, it hurts long-term growth and profit potential.

5. Who is affected? (employees, customers, investors, etc.)

• Investors/Traders (that's us!): This news creates much uncertainty. It could increase selling pressure. This might cause the stock price to fall further. If delisted, trading becomes harder and less transparent. Some brokerage platforms might not allow access. This impacts your holdings' value and tradability.
• Ernexa Employees: A delisting can deeply affect morale. It creates job insecurity. It also makes attracting and keeping top talent hard. Not raising capital well could mean less project investment. It might lead to layoffs. Compensation adjustments could also freeze.
• Company Reputation: Delisting from Nasdaq severely damages the company's image. It hurts credibility with the financial community. It also impacts potential partners and regulators. It signals financial trouble or operational issues.
• Customers/Partners: Current and future customers or partners might view Ernexa cautiously. Concerns about long-term survival and financial health could cause hesitation. They might delay new contracts or projects. They could also seek other suppliers. This is especially true for long-term or critical services.
• Competitors: Other biotech or pharma companies will watch Ernexa closely. A struggling Ernexa, especially one short on cash from delisting, creates opportunities. Competitors could gain market share. They might poach key scientists. They could also buy valuable intellectual property cheaply.

6. What happens next? (immediate and future implications)

What happens next?

• Immediately: Ernexa is not giving up. They plan to request a hearing with a Nasdaq Panel promptly. They must submit this request by March 25, 2026. It will automatically pause any delisting action. This pause lasts while the hearing process happens. This offers a temporary break. It lets the company present its case.
• In the future: The Nasdaq Panel can grant an extension. This helps Ernexa regain compliance. However, extensions are usually no longer than 180 days from the notice date. This means by September 14, 2026. Ernexa must present a full plan to the Panel. It will detail how they will meet the $1.00 minimum price rule.

This plan might include various strategies. They could improve operations to boost financial results. They might announce positive clinical trial results. Securing new funding is another option. Even another reverse stock split is possible. However, that would be very risky given their situation. However, no guarantees exist. The Panel might not rule in their favor. It might not grant an extension. Even with an extension, Ernexa might not meet the requirements. This starts a critical period for the company. Its future on a major exchange is uncertain.

7. What should investors/traders know? (practical takeaways)

For investors, here's what you should know:

• High Risk & Volatility: This situation adds significant risk to Ernexa's stock. Expect more volatility. The stock price could face downward pressure. The market is processing delisting uncertainty.
• Uncertainty: The Nasdaq hearing's outcome is very uncertain. Even with an extension, no guarantee exists. Ernexa might not fix the issues causing the low stock price.
• Research: Don't just react! Do your homework. Understand Ernexa's financial health. Look at its product pipeline and clinical trial results. Review management's plans beyond just fixing the listing issue. Decide if the company's basics justify the risk.
• Delisting Impact: If delisted, the stock would likely move to an "over-the-counter" (OTC) market. This market is less regulated. It has much lower trading volumes. Bid-ask spreads are wider. Some institutional or retail brokers might not access it. This makes buying or selling shares much harder.
• Keep an eye on: Watch for official announcements from Ernexa. These include their hearing request submission (by March 25, 2026). Also, look for details of their plan to regain compliance. Most critically, await the Nasdaq Hearing Panel's final decision. These will be key to the stock's future.

This is just an initial summary. Always do your own research. Consider your personal financial situation before trading!